Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Colin Baigent

Showing results (131-140 of 171) with videos related to

Pageof 18
Sort By:
The Lancet. Diabetes & Endocrinology|October 13, 2025
Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysisWilliam G Herrington, Zhaojing J Che, Rebecca Sardell, et al.
Eclinicalmedicine|July 21, 2025
Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trialJunwen Zhou, Claire Williams, Natalie Staplin, et al.
American Journal of Nephrology|May 7, 2026
Effects of Sacubitril/Valsartan vs Irbesartan on Urine Tubular Biomarkers in CKD: Findings from the UK HARP-III TrialMichelle A Goonasekera, Greco B Malijan, Rebecca J Sardell, et al.
The Lancet. Gastroenterology & Hepatology|January 17, 2021
Impact of the COVID-19 pandemic on the detection and management of colorectal cancer in England: a population-based studyEva J A Morris, Raphael Goldacre, Enti Spata, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 12, 2024
The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trialParminder K Judge, Katherine R Tuttle, Natalie Staplin, et al.
Lancet (London, England)|July 18, 2020
COVID-19 pandemic and admission rates for and management of acute coronary syndromes in EnglandMarion M Mafham, Enti Spata, Raphael Goldacre, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 1, 2024
Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trialKaitlin J Mayne, Rebecca J Sardell, Natalie Staplin, et al.
European Heart Journal|September 11, 2019
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular riskFrançois Mach, Colin Baigent, Alberico L Catapano, et al.
European Heart Journal|August 29, 2025
2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemiasFrançois Mach, Konstantinos C Koskinas, Jeanine E Roeters van Lennep, et al.
Atherosclerosis|August 30, 2025
2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemiasFrançois Mach, Konstantinos C Koskinas, Jeanine E Roeters van Lennep, et al.
Pageof 18

Showing results (131-140 of 171) with videos related to

Sort By:
Pageof 18
The Lancet. Diabetes & Endocrinology|October 13, 2025
Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysisWilliam G Herrington, Zhaojing J Che, Rebecca Sardell, et al.
Eclinicalmedicine|July 21, 2025
Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trialJunwen Zhou, Claire Williams, Natalie Staplin, et al.
American Journal of Nephrology|May 7, 2026
Effects of Sacubitril/Valsartan vs Irbesartan on Urine Tubular Biomarkers in CKD: Findings from the UK HARP-III TrialMichelle A Goonasekera, Greco B Malijan, Rebecca J Sardell, et al.
The Lancet. Gastroenterology & Hepatology|January 17, 2021
Impact of the COVID-19 pandemic on the detection and management of colorectal cancer in England: a population-based studyEva J A Morris, Raphael Goldacre, Enti Spata, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 12, 2024
The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trialParminder K Judge, Katherine R Tuttle, Natalie Staplin, et al.
Lancet (London, England)|July 18, 2020
COVID-19 pandemic and admission rates for and management of acute coronary syndromes in EnglandMarion M Mafham, Enti Spata, Raphael Goldacre, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 1, 2024
Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trialKaitlin J Mayne, Rebecca J Sardell, Natalie Staplin, et al.
European Heart Journal|September 11, 2019
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular riskFrançois Mach, Colin Baigent, Alberico L Catapano, et al.
European Heart Journal|August 29, 2025
2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemiasFrançois Mach, Konstantinos C Koskinas, Jeanine E Roeters van Lennep, et al.
Atherosclerosis|August 30, 2025
2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemiasFrançois Mach, Konstantinos C Koskinas, Jeanine E Roeters van Lennep, et al.
Pageof 18